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Inflammatory bowel diseases (IBDs) are chronic, idiopathic inflammations of the enteric wall associated with severe alterations of the enteric tissue architecture and functions (Neuman, 2007) . These disorders are characterized by varying periods of active disease or flare-ups and remission, with great impact on well being and patient's quality of life (Neuman, 2007) . Although the precise etiological factors leading to the onset of these chronic inflammatory conditions remain unclear, increasing evidence supports the concept that IBDs arise from altered and complex interactions of environmental, genetic and immunological factors (Torres and Rios, 2008) . In the presence of inflammatory bowel disorders, the physiological balance of enteric immune system appears completely unsettled (Baumgart and Carding, 2007) . In particular, it has been observed a marked polarization of the enteric immune response toward an uncontrolled increase in the production of pro-inflammatory mediators, which overrides the endogenous anti-inflammatory and/or healing pathways (Torres and Rios, 2008) . Such mediators can trigger the biosynthesis of further downstream factors, deeply involved in the propagation and maintenance of the inflammatory process, resulting in an excessive degree of collateral injuries to the intestinal mucosa (Camuesco et al., 2004) .
As a consequence of massive bowel inflammation, the host attempts to counteract the uncontrolled immune reactions through the activation of various mechanisms. Several lines of evidence indicate that adenosine can take a significant part in the mitigation of abnormal inflammatory responses (Antonioli et al., 2008a) . Indeed, under inflammatory conditions adenosine, through dynamic changes in the expression and/or function of its ectoenzymes, participates actively to a fine tuning of immune cellular activities, thus playing an important role in limiting the inflammatory insults to host tissues (Desrosiers et al., 2007; Antonioli et JPET # 171223 6 al., 2008b) . On the other hand, a close correlation has been found between the severity of inflammation and a local increase in both expression and activity of adenosine deaminase, the enzyme responsible for conversion of endogenous adenosine into inosine, which leads to a decreased availability of biologically active adenosine (Conlon and Law, 2004; ; Desrosiers et al., 2007) . Based on this knowledge, the pharmacological inhibition of adenosine deaminase is being regarded as a novel therapeutic approach to counteract inflammation in several pathological conditions (Adanin et al., 2002; Law et al., 2003; Kayhan et al., 2008) . In line with this concept, we previously provided evidence on the protective effects exerted by drugs acting as adenosine deaminase inhibitors against the onset of experimental colitis. In particular, we observed that, when started prior the induction of colitis, the blockade of adenosine deaminase resulted in a significant amelioration of several inflammatory parameters (Antonioli et al., 2007) .
Our previous experience has risen a number of issues which deserve further investigation.
In particular, it remains to be assessed: a) the extent of adenosine deaminase expression in inflamed colonic tissue; b) the anti-inflammatory efficacy of adenosine deaminase inhibitors in the setting of established colitis; c) the receptor pathways mediating the anti-inflammatory effects resulting from adenosine deaminase blockade. Accordingly, the present study has been designed to test the effects of adenosine deaminase inhibitors in a model of established chronic colitis as well as to clarify the mechanisms and adenosine receptor pathways involved in such anti-inflammatory activity.
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Methods
Animals
Albino male Sprague-Dawley rats, 250-300 g body weight, were employed throughout the study. The animals were fed standard laboratory chow and tap water ad libitum and were not subjected to experimental procedures for at least one week after their delivery to the laboratory. Their care and handling were in accordance with the provisions of the European Union Council Directive 86-609, recognized and adopted by the Italian Government.
Induction of colitis, drug treatments and experimental design
Colitis was induced in accordance with the method previously described by Antonioli et al. (2007) . Briefly, during a short anaesthesia with isoflurane (Abbott, Rome, Italy), 15 mg of 2,4-dinitrobenzenesulfonic acid (DNBS) in 0.25 ml of 50% ethanol were administered intrarectally via a polyethylene PE-60 catheter inserted 8 cm proximal to the anus. Control rats received 0.25 ml of 50% ethanol. Five and eleven days after DNBS or vehicle administration, rats were subjected to the evaluation of systemic and tissue inflammatory parameters as well as the expression of adenosine deaminase, in order to assess the inflammatory status and the expression pattern of the molecular target of adenosine deaminase inhibitors at the onset of drug treatments. Test drugs were administered intraperitoneally for 6 consecutive days, starting 5 days after the induction of colitis.
To select appropriate doses of test drugs, the potencies of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) and 4-amine-2-(2-hydroxy-1-decyl)pyrazole [3,4-d] pyrimidine (APP) in blocking adenosine deaminase activity were assessed in vitro by an enzyme inhibition assay, performed as reported by Antonioli et al. (2007) . The dose of dexamethasone was
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The first part of the study was aimed at evaluating the efficacy of adenosine deaminase inhibitors are effective against established colitis as well as the involvement of adenosine receptor subtypes in mediating the anti-inflammatory effects resulting from adenosine deaminase blockade. For this purpose, the effects of APP were tested, either in the absence or in the presence of selective A 1 , A 2A , A 2B and A 3 adenosine receptor antagonists, which were administered by intraperitoneal route concomitantly with APP, EHNA or dexamethasone, on systemic inflammatory parameters (food intake, body weight, spleen weight) and macroscopic score. Effective and selective doses of the receptor antagonists were chosen on the basis of previous reports (Liem et al., 2001; McLaughlin et al., 2006; Wakeno et al., 2006; Ilie et al., 2009) , and they were then validated by means of preliminary experiments in the model of DNBS-induced colitis. In this setting, increasing doses of adenosine receptor antagonists were tested against effective doses of adenosine receptor agonists on colonic myeloperoxidase (MPO) levels, a reliable index of tissue inflammatory response, thus allowing the selection of effective and selective doses of antagonists to be employed in subsequent experiments on adenosine deaminase inhibition. The mean findings on the effects of adenosine receptor antagonists versus the respective agonists are summarized in Table 1 .
The second part of the study was designed in order to gain more detailed information on the role played by adenosine receptor subtypes involved significantly in the anti-inflammatory effects exerted by the adenosine deaminase inhibitors. For this purpose, the effects of test drugs were evaluated on microscopic colonic damage as well as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA) tissue levels.
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The macroscopic score was evaluated on the whole colon, whereas microscopic and biochemical analyses were performed on tissue specimens taken from a region of inflamed colon immediately adjacent and distal to the gross necrotic damage. Therefore, at the time of sacrifice, portions of colonic tissues were immediately snap frozen in liquid nitrogen and stored at -80°C for subsequent western blot analysis, MPO, cytokine and MDA assays, or fixed in cold 4% paraformaldehyde for the assessment of microscopic damage score.
Assessment of colitis
At the end of treatments, colonic tissues were excised, rinsed with saline, and scored for macroscopic and histological damage, in accordance with the criteria previously reported by Antonioli et al. (2007) . The criteria for macroscopic scoring of colonic damage were as follows: i) presence of adhesions between colonic tissue and other organs (0 none, 1 minor, 2 major adhesions); ii) consistency of colonic faecal material (0 formed, 1 loose, 2 liquid stools); iii) presence of ulceration (0 none, 1 hyperaemia, 2 ulceration without hyperaemia, 3 ulceration with inflammation at 1 side; 4 ≥ 2 sites of ulceration and inflammation; 5 major sites of damage; 6 major sites of damage extending >2 cm). The score was then increased of 1 unit for each mm of colonic wall thickness. Microscopic damage and inflammation were assessed by light microscopy on haematoxylin/eosin-stained histological sections obtained from whole gut specimens. The histological criteria included: mucosal architecture loss (0-3); cellular infiltrate (0-3); muscle thickening (0-3); crypt abscess (0 absent, 1 present); goblet cell depletion (0 absent, 1 present). All parameters of macroscopic and histological damages were recorded and scored for each rat by two observers blinded to the treatment. At the time of experiment, the weight of spleen was also measured.
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Western blot analysis
The colonic specimens were weighed and homogenized in radioimmunoprecipitation assay To ensure the equal loading and accuracy of changes in protein abundance, the protein levels were normalized to β-actin.
JPET # 171223
1 1
Determination of tissue myeloperoxidase
In order to validate the doses of adenosine receptor antagonists to be employed against the adenosine deaminase inhibitor under study, preliminary experiments were performed to determine colonic MPO levels, as previously reported by Antonioli et al. (2007) . Briefly, colonic samples (300 mg) were homogenized three times (30 s each) at 4°C with a polytron homogenizer (Qiagen, Milan, Italy) in 1 ml of ice-cold 50 mM phosphate buffer, pH 6.0, containing 0.5% of hexadecyltrimethylammonium bromide to prevent the pseudoperoxidase activity of hemoglobin as well as to solubilize membrane-bound MPO. The homogenate was sonicated for 10 s, frozen-thawed three times, and spun by centrifugation for 20 min at 18,000g. The supernatant was then recovered and used for determination of MPO by means of a kit for enzyme-linked immunosorbent assay (Bioxytech; Oxis International Inc., Portland, OR). All samples were assayed within 2 days from collection. The results were expressed as nanograms of MPO per 100 mg of tissue.
Evaluation of tissue cytokine levels
Tissue TNF-α and IL-6 levels were measured by means of kits for enzyme-linked immunosorbent assay (Biosource International, Camarillo, CA, USA). For this purpose, tissue samples, previously stored at -80°C, were weighed, thawed and homogenized in 0.3 ml of phosphate buffered saline (PBS, pH 7.2)/100 mg of tissue at 4°C, and centrifuged at 13,400 g for 20 min. One hundred μl aliquots of the supernatants were then used for assay. Tissue TNF-α and IL-6 levels were expressed as pg per mg of tissue.
This article has not been copyedited and formatted. The final version may differ from this version. 
Drugs and reagents
and TRIzol ® were purchased from Sigma Aldrich (St Louis, Mo, USA). Erythro-9-(2-
phenoxy]-acetamide (MRS 1754) and 8-(3-chlorostyryl) caffeine (CSC) were purchased from Tocris (Bristol, UK). The synthesis of APP was performed as previously reported (Da Settimo et al., 2005) . APP, EHNA, dexamethasone, DPCPX, CSC, MRS 1754 and MRS 1191 were dissolved in sterile dimethylsulfoxide (DMSO) and further dilutions were made with sterile saline. The solutions were frozen into aliquots of 2 ml and stored at -80°C until use.
Statistical analysis
The results are given as mean ± standard error of the mean (S.E.M). The statistical significance of data was evaluated by one way analysis of variance ( 
Results
Adenosine deaminase expression
Western-blot analysis showed a detectable expression of adenosine deaminase in colonic tissues from vehicle-treated rats (Fig. 1) . In tissues from animals with colitis, the expression of adenosine deaminase was increased significantly at day 11 after the administration of DNBS (Fig. 1) .
Evaluation of colonic inflammation under control conditions
Five days after intracolonic DNBS administration, there was a significant decrease in food intake and body weight, with concomitant increments of spleen weight and bowel inflammatory parameters (macro-and microscopic damage, TNF-α, IL-6 and MDA), as compared to vehicle-treated animals (Table 2) . Likewise, at day 11 after the induction of colitis, food intake and body weight gain were lower, while other systemic and colonic indexes of inflammation were significantly increased in comparison with vehicle-treated animals, and these parameters were similar to those recorded in inflamed animals at day 5 (Table 2) .
Effects of test drugs on colonic inflammation
Food intake, body weight and spleen weight
Following a course of six-day administration to animals with established colitis, APP (15 µmol/kg/day) or EHNA (90 µmol/kg/day) ameliorated food consumption, while no significant effects on food intake were observed in rats receiving dexamethasone (0.25 µmol/kg/day) (Table 3) . Under the same conditions, the delay in body weight gain associated with colitis was counteracted after treatment with APP or EHNA (Table 3) , while dexamethasone was
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The beneficial effects exerted by APP on food intake and body weight in rats with established colitis were counteracted by administration of CSC (6 µmol/kg/day) and, to a lower extent, by MRS 1191 (7 µmol/kg/day), while no significant effects were obtained with the A 1 or A 2B receptors antagonists DPCPX (4 µmol/kg/day) and MRS 1754 (2 µmol/kg/day), respectively ( Fig. 2 ). In addition, the effects of APP administration on spleen weight were blunted by the A 2A receptor antagonist, while no significant effects were observed in the presence of the other receptor antagonists (Fig.2) . Moreover, the adenosine receptor antagonists did not exert any significant influence on food intake, body weight or spleen weight when tested alone (Fig. 2) .
Macroscopic damage
Animals with colitis treated with APP (15 µmol/kg/day), EHNA (90 µmol/kg/day) or dexamethasone (0.25 µmol/kg/day) for six days displayed a significant reduction in the macroscopic damage score (Fig. 3A) . The adenosine receptor antagonists did not modify the macroscopic damage associated with chronic colitis when tested alone (Fig 3B) . However, CSC (6 µmol/kg/day) prevented the ameliorative effects exerted by APP, while no appreciable effects were observed with the administration of DPCPX (4 µmol/kg/day), MRS
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Microscopic damage
Colonic specimens obtained from inflamed rats treated with APP (15 µmol/kg/day) showed a significant improvement in microscopic scores (Fig. 4A) . Similarly, EHNA (90 µmol/kg/day) or dexamethasone (0.25 µmol/kg/day) induced a significant amelioration of histological damage (Fig. 4A ). The A 2A or A 3 receptor antagonist did not affect the microscopic damage of inflamed colon when tested alone (Fig 4B) . The beneficial effects exerted by APP or EHNA on the microscopic patterns of colonic inflammation were markedly counteracted by the concomitant administration of CSC and, to a lower extent, by MRS 1191 (Fig. 4B ). The A 2A or A 3 receptor antagonist did not show significant effects in dexamethasone-treated rats (Fig. 4B ).
TNF-α and IL-6 levels in colonic tissues
Treatments with APP (15 µmol/kg/day), EHNA (90 µmol/kg/day) or dexamethasone (0.25 µmol/kg/day) significantly decreased the concentrations of TNF-α and IL-6 in the inflamed colonic tissues (Fig. 5A and 6A ). CSC or MRS 1191 were without effects on TNF-α and IL-6 when administered alone to inflamed rats. However, the blockade of A 2A or A 3 receptors counteracted the decrease in TNF-α and IL-6 tissue levels induced by APP or EHNA in animals with colitis ( Fig. 5B and 6B ). The ameliorative effects of dexamethasone were unaffected by treatment with CSC or MRS 1191 ( Fig. 5B and 6B ).
MDA levels in colonic tissues
Treatments with APP (15 µmol/kg/day), EHNA (90 µmol/kg/day) or dexamethasone (0.25 µmol/kg/day) significantly attenuated the increase in colonic MDA levels associated with established colitis (Fig. 7A) . 
Discussion
The present study was performed to investigate the efficacy of adenosine deaminase blockade against established colitis, as well as to characterize the adenosine receptors which are recruited by endogenous adenosine following its preservation from catabolic inactivation.
In order to pursue these aims, the effects of the novel adenosine deaminase inhibitor APP and its standard comparator EHNA were assayed during the chronic phase of colitis elicited by DNBS, and dexamethasone was used as a comparator with known anti-inflammatory activity to assess the relative anti-inflammatory potency of both adenosine deaminase inhibitors. In this curative dosing protocol, the administration of test drugs was started five days after DNBS administration, when chronic colonic inflammation was fully established (Tran et al., 1999) . At this stage, and up to day 11, the inflammation was associated with reduced weight gain, diarrhea, mucosal ulceration and bowel wall thickening. Significant increments of inflammatory cytokines (TNF-α, IL-6) and oxidation products (MDA) were also recorded in the inflamed colon. All these observations support the evidence that from day 5 to 11 after DNBS administration there was a steadily active inflammatory response of colon resulting from an abnormal activity of inflammatory cells infiltrating the intestinal tissue.
Our molecular analysis provided the first demonstration that a significant increase in adenosine deaminase expression occurs at level of the inflamed colonic tissue. In keeping with our observation, previous studies have reported increments of adenosine deaminase expression and activity in different models of inflammation, including sepsis, small bowel enteritis and hypoxia (Cohen et al., 2002; Eltzschig et al., 2006) , as well as in the serum of patients with rheumatoid arthritis (Sari et al., 2003) or pancreatitis (Ibis et al., 2007) .
However, the cellular localization of adenosine deaminase in normal or inflamed colonic tissues was not investigated in the present study, and it remains to be established whether the adenosine-dependent anti-inflammatory activity mediated by tonic A 2A or A 3 receptors stimulation. As far as A 2B receptors are concerned, previous reports showed conflicting evidence about their anti/pro-inflammatory role during intestinal inflammation (Kolachala et al., 2008; Frick et al., 2009 ). In our study, A 2B receptors did not appear to be significantly involved in the modulation of colonic inflammatory response. This discrepancy could depend on a number of differences between the present work and those mentioned above. In particular, there are differences in species, experimental model of bowel inflammation, and drug administration protocol. Moreover, in our preliminary experiments the administration of NECA was associated with an increase in colonic myeloperoxidase levels, thus suggesting that the exogenously induced activation of A 2B receptors is likely to promote proinflammatory effects (Antonioli et al., unpublished data) . For these reasons, it is conceivable that in the setting of the present study, A 2B receptors were not able to take a significant part to the anti-inflammatory response resulting adenosine deaminase blockade.
Overall, the present results suggest that the pharmacological modulation of adenosine deaminase represents a novel and promising therapeutic strategy for the management of bowel inflammation. Indeed, the specific and selective inhibition of this enzyme, markedly expressed in inflamed bowel tissues, produced ameliorative effects against an established inflammatory environment, acting on several aspects of the inflammatory reaction. Most importantly, the enhanced levels of endogenous adenosine, resulting from adenosine deaminase inhibition, down-regulated the production of key pro-inflammatory cytokines, Treatments with test dru gs were started at day 5 from the induction of colitis with DNBS; systemic parameters of inflammation were assessed on day 11. 
